


Access Challenges for Branded Medicines in Medicare Part D

At the 20th anniversary of Part D, IQVIA research finds that exclusions and coverage restrictions have expanded, resulting in delayed or limited access to branded medicines for many patients



*2024 analysis includes data through September 2024 for Migraine, Pulmonary Arterial Hypertension (PAH), Multiple Sclerosis (MS), and Osteoporosis. The other classes have data for full year 2024.

47%


of first fill attempts for branded medicines were initially rejected in Part D in 2025

37% → 47%

increase in initial rejection rates since 2021

32%

of initially rejected patients remained unable to access their branded product of choice within one year



Despite Inflation Reduction Act (IRA) requirement to cover drugs selected under the Medicare Drug Price Negotiation Program (MDPNP):

- Nearly **24%** of first fill attempts for Initial Price Applicability Year (IPAY) 2026-selected drugs were rejected in 2026
- **Higher rejection rates** were observed for immunology (59%) and oncology (67%)
- Rejection rates were **largely unchanged** following MDPNP implementation

Note: This report and the analyses used were sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA). The findings and points of view are the result of IQVIA's investigation and expertise.
Data: IQVIA LAAD; New Patients; Branded Medicines; Medicare Part D; 2021-Q1 2026; Averages are weighted by brand volume.
Source: U.S. Market Access Strategy Consulting analysis.